Daily Respiratory Research Analysis
Analyzed 414 papers and selected 3 impactful papers.
Summary
A multicenter randomized trial showed that EBUS-guided transbronchial mediastinal cryobiopsy substantially outperforms EBUS-TBNA for diagnosing non-metastatic mediastinal lymphadenopathy, largely sarcoidosis, with comparable safety. A single-center randomized trial identified a simple, optimized ventilator strategy that prevents pressure-alarm–limited ventilation during bronchoscopy in intubated patients. In addition, a large multicenter study developed and externally validated a machine learning model using routine blood tests to accurately stratify community-acquired pneumonia severity.
Research Themes
- Minimally invasive diagnostics for mediastinal lymphadenopathy
- Procedural safety and ventilator optimization during bronchoscopy
- Data-driven triage for community-acquired pneumonia
Selected Articles
1. EBUS-guided transbronchial mediastinal cryobiopsy for diagnosing non-metastatic lymphadenopathy: A randomized controlled trial.
In a multicenter randomized trial, EBUS-guided transbronchial mediastinal cryobiopsy achieved a significantly higher diagnostic yield than EBUS-TBNA for non-metastatic lymphadenopathy, especially sarcoidosis, with only mild (grade 1) airway bleeding observed. These results support TBMC as a potential first-line diagnostic approach in mediastinal/hilar nodes.
Impact: This is the first randomized comparison demonstrating superior diagnostic performance of EBUS-TBMC over EBUS-TBNA for benign lymphadenopathy, potentially changing diagnostic algorithms for sarcoidosis and other non-metastatic nodal diseases.
Clinical Implications: For patients with suspected sarcoidosis or benign mediastinal lymphadenopathy, EBUS-guided cryobiopsy may serve as a first-line tissue acquisition method to improve diagnostic yield while maintaining safety.
Key Findings
- EBUS-TBMC had a higher overall diagnostic yield than EBUS-TBNA (97.1% vs 79.9%; p<0.001).
- Sensitivity for sarcoidosis was superior with TBMC (98.0% vs 82.7%; p<0.001).
- Safety profile was acceptable with only grade 1 airway bleeding reported in all patients.
Methodological Strengths
- Multicenter randomized design with head-to-head comparison.
- Pre-specified primary outcome (diagnostic yield) with subgroup analysis for sarcoidosis.
Limitations
- Population was predominantly sarcoidosis, which may limit generalizability to other benign etiologies.
- Short-term safety reporting; long-term adverse event monitoring not detailed.
Future Directions: Prospective studies across diverse benign etiologies and standardized TBMC protocols, including needle-knife selection and freezing parameters, with cost-effectiveness and long-term safety.
BACKGROUND: Non-metastatic lymphadenopathy is challenging to diagnose. The comparative diagnostic performance of endobronchial ultrasound (EBUS)-guided transbronchial mediastinal cryobiopsy (TBMC) vs. EBUS-transbronchial needle aspiration (TBNA) remains debated. METHODS: This multicenter randomized trial was conducted in three hospitals. Patients with at least one mediastinal and/or hilar lesion of ≥1 cm in the short axis who required diagnostic bronchoscopy were included. The patients were randomized in a 1:1 ratio to receive either EBUS-TBNA followed by EBUS-TBMC (EBUS-TBNA-first group) or EBUS-TBMC followed by EBUS-TBNA (EBUS-TBMC-first group). The primary outcome was the diagnostic yields of EBUS-TBMC and EBUS-TBNA. FINDINGS: The overall diagnostic yield of EBUS-TBMC for non-metastatic lymphadenopathy was significantly higher than that of EBUS-TBNA for specific benign etiologies and lymphomas (97.1% vs. 79.9%, p < 0.001). In the subgroup analysis, EBUS-TBMC showed a higher sensitivity for sarcoidosis than EBUS-TBNA (98.0% vs. 82.7%, p < 0.001). All patients experienced grade 1 airway bleeding. CONCLUSIONS: EBUS-TBMC demonstrated a higher diagnostic yield than EBUS-TBNA for non-metastatic lymphadenopathy in a cohort almost exclusively composed of sarcoidosis cases, with a good safety profile. EBUS-TBMC is a potential first-line diagnostic tool for non-metastatic lymphadenopathy. FUNDING: This work was financially supported by the Noncommunicable Chronic Diseases-National Science and Technology Major Project (2024ZD0528900 and 2024ZD0528902 to G.H.).
2. Ventilator settings for fiberoptic bronchoscopy during mechanical ventilation: a randomized adjudicator-blinded controlled trial VentSetFib.
In intubated adults undergoing bronchoscopy, a simple ventilator bundle (low inspiratory flow, small tidal volume, fixed inspiratory time, moderate rate and PEEP) reduced pressure-alarm–limited ventilation from 96% to 4% compared with conventional settings, without increasing respiratory or circulatory complications. Crossover data confirmed reversibility and effectiveness.
Impact: This pragmatic trial delivers immediately actionable guidance to prevent intra-procedural ventilation failure during bronchoscopy in the ICU, addressing a common and consequential safety problem.
Clinical Implications: Adopt bronchoscopy-optimized ventilator settings for intubated patients (e.g., flow ≤25 L/min, VT 5 mL/kg, inspiratory time 1–1.3 s, RR 16/min, PEEP 5 cmH2O) to maintain adequate ventilation and avoid pressure-alarm–limited failure.
Key Findings
- Primary endpoint reduced from 96% (conventional) to 4% (optimized) (p<0.001).
- Conventional settings led to lower delivered VT (median 160 vs 400 mL) and minute ventilation (3.2 vs 7.2 L/min).
- Safety was comparable; crossover confirmed improved pressures and ventilation when switching to optimized settings.
Methodological Strengths
- Randomized, adjudicator-blinded controlled design.
- Objective ventilatory endpoints with crossover confirmation.
Limitations
- Single-center study may limit generalizability.
- Short-term intra-procedural outcomes; no longer-term clinical endpoints.
Future Directions: Multicenter validation and integration into bronchoscopy protocols; explore tailoring for different lung mechanics and ARDS phenotypes.
BACKGROUND: During bronchoscopy in mechanically ventilated patients, bronchoscope insertion markedly increases airway resistance, elevating peak airway pressure and reducing delivered tidal volume. We sought to determine whether specific ventilator settings (assist volume-controlled with reduced inspiratory flow and tidal volume) lower serious adverse events during flexible fiberoptic bronchoscopy compared with conventional ventilator settings. METHODS: Single-center randomized adjudicator-blinded controlled trial in intubated adult patients undergoing fiberoptic bronchoscopy. Patients were assigned (1:1) to bronchoscopy-optimized settings (inspiratory flow ≤ 25L/min, tidal volume = 5mL/Kg, 1s ≤ inspiratory time ≤ 1.3s, respiratory frequency = 16 breaths/min, positive end-expiratory pressure = 5cmH RESULTS: The primary composite endpoint occurred in 1/23 (4%) with optimized settings compared with 22/23 (96%) with conventional settings (risk difference -91.3%; risk ratio 0.05; p < 0.001). Events were driven by ventilatory failure due to pressure-alarm limitation, with lower delivered tidal volume (median 160 vs 400 mL; p < 0.001) and minute ventilation (3.2 vs 7.2 L/min; p < 0.001) under conventional settings. Respiratory and circulatory events were rare and similar between groups (each 1/23 [4%]). Among 19 crossover patients, switching to optimized settings reduced peak airway pressure and restored adequate ventilation. CONCLUSIONS: A bronchoscopy-optimized ventilation strategy substantially reduces pressure-alarm-limited ventilation events and enables the delivery of adequate ventilatory support during fiberoptic bronchoscopy.
3. A machine learning-based model for assessing community-acquired pneumonia severity using routine blood tests.
Using routine blood indices alone, a nine-feature random forest model classified severe vs. mild CAP with AUC ~0.95 in both development (n=3,127) and external validation (n=2,087) cohorts. Decision-curve analysis indicated net clinical benefit across thresholds, and a web application enables bedside use.
Impact: Provides an immediately deployable, low-cost triage tool that leverages existing laboratory workflows to support rapid CAP severity assessment and resource allocation.
Clinical Implications: Hospitals can integrate the validated model into ED workflows to prioritize monitoring, imaging, and ICU referral for likely severe CAP using routine labs available at presentation.
Key Findings
- Random forest with 9 routine blood features achieved AUC 0.95 in both discovery and validation cohorts.
- Decision curve analysis showed consistent net clinical benefit across decision thresholds.
- The model was implemented as a web application for clinical use.
Methodological Strengths
- Large, multicenter cohorts with external validation.
- Transparent performance reporting (AUC, AUPRC, PPV/NPV, F1) and decision-curve analysis.
Limitations
- Retrospective case-control design may introduce selection bias.
- Model calibration and performance in other health systems/populations require further validation.
Future Directions: Prospective impact analysis, EHR integration with automated alerts, and head-to-head comparisons with existing clinical scores (e.g., CURB-65, PSI).
BACKGROUND: The choice of first-line therapy for community-acquired pneumonia (CAP) depends on disease severity. However, quickly and accurately differentiating mild from severe CAP patients remains challenging. This study aims to evaluate the performance of machine learning-based diagnostic models employing routine blood indicators to distinguish CAP severity. METHODS: A multicenter, retrospective, case-control study conducted at Xuhui Central Hospital (Discovery cohort), and Putuo People's Hospital (Validation cohort), from January 2016 to January 2024. Patients were further classified into mild or severe CAP according to the IDSA/ATS criteria. Routine blood tests were performed with an automatic blood cell analyzer. Twelve machine learning-based diagnostic models were developed from routine blood indicators for differentiating between mild and severe CAP. RESULTS: A total of 3,127 (1,612 mild, 1,615 severe) and 2,087 participants (1,072 mild, 1,015 severe) were included in the discovery and validation cohorts, respectively. Of the 12 models developed, the random forest (RF) model showed the best performance with 9 routine blood indicators. In the discovery cohort, the model achieved an AUC of 0.95, an AUPRC of 0.94, a positive predictive value of 0.89, a negative predictive value of 0.88, an accuracy of 0.89, and an F1 score of 0.89, while in the validation cohort, it demonstrated similar performance, with values of 0.95, 0.94, 0.88, 0.87, 0.88, and 0.87, respectively. Decision curve analysis confirmed consistent net benefits from the model across all threshold probabilities. The RF model was integrated into a web application for clinical use. CONCLUSION: We successfully developed a nine-feature RF model with promising value for differentiating mild from severe CAP patients.